PHARMACEUTICALS
Articles and editorials
'91 Memo Warned of Mercury in Shots, H482 [9FE]
Avian Flu Virus Could Hide in Ducks, S8447 [19JY]
Bigger Than the Social Security Crisis—Wasteful Spending on Prescription Drugs, E1162 [8JN]
Bird Flu Drug Rendered Useless—Chinese Chickens Given Medication Made for Humans, S8448 [19JY]
Brazil Mulls Drug Patent Theft as an AIDS Antidote, E1436 [1JY]
Bush Should Feel Doctors' Pain, E692 [19AP]
California Helped Pay for 137 Sex Offenders' Viagra—State Agencies Directed To Stop Providing Such Drugs to Ex-Convicts, H5037 [23JN]
Congress, on Drugs—Helping Their Friends in the Pharmaceutical Industry, S14143 [20DE]
Deadly Flu Strain Shows Up in Migratory Birds—Scientists' Discovery Gives Rise to Fears the Virus Could Spread Beyond East Asia, S8448 [19JY]
Deadly Immunity, H5074-H5077 [23JN]
Drug Makers Don't Need Gift, S14143 [20DE]
Financing Drug Research—What Are the Issues?, E1159 [8JN]
Learn From Past Vaccines—Drug Firms Don't Deserve Virtually Unlimited Protection Against Vaccine Lawsuits, S14145 [20DE]
Naughty Pursuit of Secrecy, S14144 [20DE]
Pandering Pandemic, S14144 [20DE]
Richman? Poorman? Beggarman? Thief?, E1435 [1JY]
Seniors Try To Decipher Drug Options, H9935 [7NO]
Stealth Liability Provision, S14142 [20DE]
Threat Worse Than Terror, S11960 [27OC]
Trading on Fear To Pass Vaccine Legislation Is Wrong, S14143 [20DE]
U.S. Blocks Drugs Sent From Canada, H1329 [10MR]
Unprepared for a Flu Pandemic, S8448 [19JY]
Vaccine Makers—Lawmakers Service People, Not Drug Companies, S14143 [20DE]
Vaccines and Accountability—Bush's Proposal To Shield Avian-Flu Vaccine Makers From Liability Invites Health Problems, S14145 [20DE]
Vaccines Come With Risk, S14143 [20DE]
Vaccines—Shot in the Dark, S14144 [20DE]
Veterans Angered by Official's Comments, H517 [9FE]
Wrong-Way Immunity, S14145 [20DE]
Bills and resolutions
Advertising: prohibit as indecent the broadcasting of any advertisement for a medication for the treatment of erectile dysfunction (see H.R. 1420), H1693 [17MR]
Anabolic Steroid Control Act: technical corrections (see S. 893), S4184 [25AP]
Armed Forces: prohibit requirement of anthrax and smallpox immunizations without members' consent and correct records of those previously punished for refusing such vaccines (see H.R. 514), H347 [2FE]
China, People's Republic of: adhere to internationally recognized health standards by prohibiting use of antiviral medication to protect livestock (see H. Res. 377), H6381 [22JY]
Computers: standardize certification of Internet pharmacies and prohibit certain advertising by, and use of certain bank instruments for purchases from, illegal Internet pharmacies (see H.R. 1808), H2471 [21AP]
Consumers: provide tax credit to retirement age individuals, remove barriers to importation, and prohibit certain regulation of Internet sites relative to prescription drugs (see H.R. 578), H351 [2FE]
Contraceptives: require equitable coverage of drugs, devices, and services under health insurance plans (see S. 1214), S6299 [9JN] (see H.R. 4651), H13188 [22DE]
Controlled Substances Act: amend relative to distribution of pseudoephedrine (see H.R. 1056), H940 [2MR]
———amend relative to regulation of ephedrine alkaloids (see H.R. 1083), H981 [3MR] (see H.R. 1378), H1691 [17MR]
———prohibit third-party Internet sales sites from posting offers to sell controlled substances (see H.R. 3608), H7561 [28JY]
Dept. of Defense: require emergency contraception to be available at all military health care treatment facilities (see H.R. 2635), H4073 [25MY]
Dept. of HHS: establish the National Vaccine Authority (see H.R. 4396), H11033 [18NO]
———promulgate regulations for the reimportation of prescription drugs (see S. 109), S144 [24JA]
Dept. of Veterans Affairs: conduct a study of the accuracy of expiration dates on certain prescription drugs maintained by the Dept. (see H.R. 1149), H1023 [8MR]
———dispense medications to veterans for prescriptions written by private practitioners (see H.R. 693), H521 [9FE] (see H.R. 1585), H1895 [12AP]
———permit Medicare-eligible veterans to receive an outpatient medication benefit (see S. 614), S2644 [14MR]
———require filling of prescriptions for drugs and medicines written by private physicians (see H.R. 2379), H3331 [16MY]
Diseases: establish programs and activities to increase influenza vaccination rates through the provision of free vaccines (see S. 2112), S13659 [15DE]
———improve and secure an adequate supply of influenza vaccine (see S. 1828), S11212 [6OC]
———improve preparation for an influenza pandemic, including an avian influenza pandemic (see S. 969), S4547 [28AP] (see S. 1821), S11130 [5OC] (see H.R. 3369), H6204 [20JY] (see H.R. 4062), H8846 [17OC] (see H.R. 4245), H9962 [7NO] (see H.R. 4603), H12048 [16DE]
———promote initiatives to develop an HIV vaccine (see S. Res. 42), S1050 [7FE] (see H. Res. 286), H3556 [18MY]
———provide assistance to countries to combat tuberculosis, malaria, and other infectious diseases (see S. 950), S4546 [28AP]
———provide for emergency distributions of influenza vaccine (see H.R. 4358), H10908 [17NO]
Drugs: accelerate efforts to develop vaccines for diseases primarily affecting developing countries (see S. 1698), S10037 [14SE] (see H.R. 3781), H7949 [14SE]
———authorize the Dept. of HHS to negotiate prices for Medicare outpatient prescription drugs and include prices charged to certain Federal agencies in determining best price for Medicaid outpatient drugs (see H.R. 2200), H3055 [5MY]
———delay implementation of voluntary prescription drug benefit program, extend Medicare prescription drug discount card and transitional assistance programs, and Medicaid coverage of prescription drugs (see H.R. 1382), H1692 [17MR]
———eliminate safe-harbor exception for certain packaged pseudoephedrine products used in manufacturing methamphetamine (see H.R. 1350), H1621 [16MR] (see H.R. 1446), H1694 [17MR]
———establish an electronic controlled substances monitoring program in each State (see S. 518), S2004 [3MR]
———establish certain restrictions on drugs containing isotretinoin, including the drug marketed as Accutane (see H.R. 2956), H4655 [16JN]
———establish electronic systems in each State for practitioner monitoring of the dispensing of certain controlled substances (see H.R. 1132), H983 [3MR]
———establish fairer pricing for prescription drugs for individuals without access to discounted prices (see H.R. 1655), H2101 [14AP]
———expand the clinical trials drug data bank (see S. 470), S1794 [28FE]
———expand the scope of information required for the data bank on clinical trials for drugs (see H.R. 3196), H5602 [30JN]
———include dehydroepiandrosterone as an anabolic steroid (see S. 1137), S6021 [26MY] (see H.R. 3937), H8513 [28SE]
———prevent illegal importation of controlled substances (see S. 400), S1513 [16FE]
———prohibit Federal payment or reimbursement for drugs prescribed for the treatment of sexual or erectile dysfunction (see S. 1113), S5851 [24MY] (see H.R. 3566), H7559 [28JY]
———prohibit Federal payment or reimbursement for drugs prescribed to sex offenders for the treatment of sexual or erectile dysfunction (see S. 1126), S5921 [25MY] (see H.R. 2814), H4295 [8JN]
———protect the public from unsafe importation of prescription drugs and from counterfeit prescription drugs (see S. 184), S574 [26JA] (see H.R. 753), H582 [10FE]
———provide discounts to Medicaid and other Federal programs for the advertising costs of certain prescription drugs and ensure that these drugs are prescribed based on health needs rather than marketing (see S. 1128), S6021 [26MY]
———provide for importation of pharmaceutical products under a compulsory license as provided for under the World Trade Organization (see H.R. 4392), H11033 [18NO]
———provide incentives for investment in research and development of new medicines and to enhance access to new medicines (see H.R. 417), H235 [26JA]
———provide incentives to companies to invest in research and development of antibiotic drugs, antivirals, diagnostic tests, and vaccines that may be used to identify, treat, or prevent an infectious disease (see H.R. 3154), H5600 [30JN]
———transfer ephedrine, pseudoephedrine, and phenylpropanolamine to schedule V of the schedules of controlled substances (see H.R. 3568), H7559 [28JY] (see H.R. 3955), H8642 [29SE]
———withdraw the drug OxyContin from the commercial market (see H.R. 2195), H3054 [5MY]
FDA: determine whether to allow marketing of emergency-contraceptive drug Plan B as a prescription drug for women 15 or younger and a nonprescription drug for women 16 or older (see H.R. 4229), H9641 [3NO]
———ensure autonomy and eliminate conflicts-of-interest relative to drug company fees and advisory panels, improve postmarket drug safety, regulate off-label uses, and clarify liability for approved drugs (see H.R. 2090), H2976 [4MY]
———establish therapeutic equivalence requirements for generic drugs (see H.R. 2299), H3198 [11MY]
———improve ability to ensure drug safety (see S. 930), S4398 [27AP] (see H.R. 4429), H11034 [18NO]
———prohibit the approval of any drug that infringes the right to life (see H.R. 3553), H7558 [28JY]
———require prior approval of advertisements for prescription drugs and restricted medical devices (see H.R. 3696), H7812 [8SE]
———withdraw approved application for the drug known as RU-486 and review process by which the FDA approved such drug (see S. 511), S2004 [3MR] (see H.R. 1079), H981 [3MR]
Federal Food, Drug, and Cosmetic Act: enhance criminal penalties for certain violations involving concealment of evidence of a serious adverse drug experience (see H.R. 870), H719 [16FE]
———establish recall authority for drugs and increase criminal penalties for sale or trade of knowingly adulterated or misbranded prescription drugs (see S. 1978), S12606 [9NO] (see H.R. 2345), H3261 [12MY]
———establish recall authority for drugs and increase criminal penalties for sale or trade of prescription drugs knowingly adulterated or misbranded (see H.R. 1396), H1692 [17MR]
———establish requirements to allow sale of prescription drugs over the Internet (see S. 399), S1513 [16FE] (see H.R. 840), H717 [16FE]
———preserve effectiveness of medically important antibiotics used in treatment of human and animal diseases (see S. 742), S3358 [7AP] (see H.R. 2562), H3892 [24MY]
———prohibit sale or trade of prescription drugs that were knowingly adulterated or misbranded (see H.R. 2600), H3893 [24MY]
———reduce human exposure to mercury through vaccines (see S. 1422), S8487 [19JY] (see H.R. 881), H791 [17FE]
Foreign countries: remove all embargoes on food, medicine, and medical supplies (see H.R. 1527), H1845 [6AP]
Foreign trade: impact of illegal importation of prescription drugs on regulatory protections afforded consumers (see H. Con. Res. 75), H796 [17FE]
Government regulations: drug and medical device approval process, H815 [1MR]
———importation of prescription drugs (see S. 334), S1198 [9FE] (see H.R. 328), H194 [25JA] (see H.R. 700), H521 [9FE]
Health: conduct vaccine awareness campaign, ensure sufficient vaccine supply, prepare for pandemic or epidemic, and encourage vaccine production capacity relative to influenza (see S. 375), S1413 [15FE] (see H.R. 628), H410 [8FE] (see H.R. 813), H628 [15FE]
———establish reasonable legal reforms that will facilitate the manufacture of vital, life-saving vaccines (see H.R. 650), H411 [8FE]
———improve accessibility to and administration of immunizations against vaccine-preventable diseases, including influenza (see S. 1527), S9284 [28JY] (see H.R. 3502), H7556 [28JY]
———improve patient safety and reduce incidence of medical errors (see S. 544), S2244 [8MR] (see H.R. 3205), H5739 [12JY]
———permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests (see H.R. 2792), H4295 [8JN]
———promote a culture of safety within the health care system through the establishment of a National Medical Error Disclosure and Compensation Program (see S. 1784), S10594 [28SE]
———provide a drug discount program for individuals without prescription drug coverage (see H.R. 3956), H8643 [29SE]
———require notification by manufacturers before discontinuing production of a vaccine and develop a national vaccine stockpile (see S. 226), S738 [1FE]
Health care facilities: allow qualifying children's hospitals to participate in the 340B drug discount program (see H.R. 4036), H8808 [7OC]
———implement computerized order entry systems in hospitals and skilled nursing facilities to reduce medication errors and increase efficiency (see H.R. 3607), H7561 [28JY]
———provide for public disclosure of charges for certain hospital and ambulatory surgical center services and drugs (see H.R. 3139), H5599 [30JN]
———provide for public disclosure of charges for certain hospital services and drugs (see S. 1827), S11212 [6OC]
Health care professionals: clarify responsibilities of a pharmacy when a staff pharmacist refuses to fill a valid prescription for a drug on the basis of religious beliefs or moral convictions (see S. 809), S3653 [14AP] (see H.R. 1539), H1850 [8AP] (see H.R. 1652), H2101 [14AP]
———ensure integrity in the operation of pharmacy benefit managers (see H.R. 1669), H2102 [14AP]
India: provide assistance to combat HIV/AIDS (see S. 674), S2995 [17MR] (see H.R. 1408), H1693 [17MR]
Insurance: require comprehensive coverage for childhood immunizations (see H.R. 277), H137 [6JA]
Japan: urge honoring of commitments under the Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals (see S. Con. Res. 67), S13362 [18NO] (see H. Con. Res. 311), H11220 [7DE]
Medicaid: extend prescription drug rebate program to enrollees of managed care organizations (see S. 1585), S9467 [29JY]
———provide health information technology grants to States and reduce number of medical and medication errors, unnecessary hospitalizations, infections, and inappropriate care (see H.R. 4142), H9102 [25OC]
———provide public disclosure of average manufacturer prices and best prices for prescription drugs (see H.R. 3546), H7558 [28JY]
———require drug manufacturers to report the average manufacturer price and the best price of authorized generic drugs and any other drugs sold under a certain new drug application to the Dept. of HHS (see S. 1903), S11665 [20OC]
———require drug utilization review programs to deny coverage of erectile dysfunction drugs for individuals registered (or required to be registered) as sex offenders (see H.R. 2648), H4138 [26MY]
Medicare: assure cost credibility of the prescription drug benefit (see H.R. 729), H523 [9FE]
———condition the payment of employer prescription drug subsidies on the maintenance of current prescription drug benefits (see H.R. 655), H411 [8FE]
———contain costs of prescription drug program (see S. 581), S2383 [9MR] (see H.R. 918), H793 [17FE]
———continue Medicaid prescription drug coverage to dual-eligible beneficiaries for a certain period while allowing part D benefits to be implemented as scheduled (see S. 566), S2245 [8MR] (see H.R. 1144), H1023 [8MR]
———coverage of immunosuppressive drugs for beneficiaries who receive an organ transplant (see S. 173), S573 [26JA]
———coverage of immunosuppressive drugs for beneficiaries who receive an organ transplant without regard to when the transplant was received (see H.R. 3633), H7612 [29JY]
———delay implementation of prescription drug benefit for individuals who are not lowest-income subsidy eligible individuals (see H.R. 3870), H8340 [22SE]
———deliver a meaningful benefit and lower prescription drug prices (see S. 345), S1260 [10FE] (see S. 873), S4108 [21AP] (see H.R. 752), H582 [10FE]
———deliver a meaningful benefit and lower prescription drug prices (H.R. 752), consideration (see H. Res. 584), H11109 [6DE]
———ensure that prescription drug benefits have no impact on benefits under other Federal programs (see S. 1179), S6154 [7JN] (see H.R. 2746), H4186 [7JN]
———establish criminal penalties for defrauding individuals relative to enrollment in a prescription drug plan (see H.R. 4406), H11033 [18NO]
———exclude coverage of drugs prescribed for treatment of impotence (see H.R. 712), H522 [9FE]
———extend implementation of prescription drug program (see H.R. 3940), H8642 [29SE]
———extend initial enrollment period for prescription drug benefits, waive penalties for late enrollment, and provide other additional beneficiary protections (see H.R. 4410), H11034 [18NO]
———extend initial enrollment period for prescription drug benefits and waive penalties for late enrollment (see H.R. 4399), H11033 [18NO]
———improve accountability in the Medicare Advantage and prescription drug programs (see H.R. 4103), H9042 [20OC]
———improve coordination of prescription drug coverage under retiree plans and State pharmaceutical assistance programs with Medicare drug benefits (see H.R. 152), H76 [4JA]
———improve coordination of prescription drug coverage under State pharmaceutical assistance programs with Medicare drug benefits (see S. 764), S3481 [12AP] (see H.R. 1572), H1894 [12AP]
———improve voluntary prescription drug benefit and provide greater access to affordable pharmaceuticals (see H.R. 4395), H11033 [18NO]
———negotiate for lower prices for prescription drugs (see S. 813), S3734 [15AP]
———negotiate for lower prices for prescription drugs, eliminate gap in coverage of prescription drug benefits, and promulgate regulations for the reimportation of prescription drugs (see H.R. 1626), H1969 [13AP]
———permit negotiation of fair prices for, and allow the reimportation of, prescription drugs (see S. 239), S738 [1FE]
———permit the Dept. of HHS to enter into direct negotiations to promote the best prices for beneficiaries (see H.R. 376), H233 [26JA]
———permit the Dept. of HHS to enter into direct negotiations to promote the best prices for beneficiaries (H.R. 376), consideration (see H. Res. 267), H3055 [5MY]
———prevent a decrease in benefits resulting from part D premiums increases (see H.R. 3637), H7612 [29JY]
———protect enrollees eligible for prescription drug benefit coverage from abusive marketing practices (see H.R. 4645), H12289 [18DE]
———provide additional beneficiary protections (see H.R. 2487), H3693 [19MY]
———provide beneficiaries prescription drugs at reduced prices (see H.R. 2685), H4140 [26MY]
———provide beneficiaries with access to prescription drugs at Federal Supply Schedule prices (see H.R. 4610), H12049 [16DE] (see H.R. 4652), H13189 [22DE]
———provide continued coverage for immunosuppressive drugs furnished to beneficiaries that have received an organ transplant and whose coverage would otherwise expire (see H.R. 2051), H2879 [3MY]
———provide extended and additional protection to beneficiaries enrolled in prescription drug benefit plans (see S. 1841), S11212 [6OC] (see H.R. 3861), H8340 [22SE]
———provide extended and additional protection to beneficiaries enrolled in prescription drug benefit plans (H.R. 3861), consideration (see H. Res. 585), H11109 [6DE]
———provide for negotiation of fair prices for prescription drugs (see S. 123), S145 [24JA] (see S. 445), S1623 [17FE]
———provide incentives to physicians for writing electronic prescriptions (see S. 1910), S11768 [24OC]
———remove exclusion of benzodiazepines from required coverage under the prescription drug program (see H.R. 3151), H5600 [30JN]
———repeal Medicare Advantage Regional Plan Stabilization Fund (see S. 124), S145 [24JA]
———require that prescription drug plans or Medicare Advantage-Prescription Drug plans with initial coverage limits obtain signed certification prior to enrolling benficiaries (see S. 2026), S12949 [16NO]
———require the negotiation and disclosure of the lowest possible prices for prescription drugs and permit beneficiaries to import prescription drugs from Canada (see H.R. 563), H351 [2FE]
Medicare/Medicaid: assist pharmacies in facilitating enrollment of dual eligible populations under the prescription drug benefit (see S. 2173), S14317 [21DE]
———eliminate coverage of drugs when used for treatment of erectile dysfunction (see H.R. 3543), H7558 [28JY]
———ensure that pharmacies receiving reimbursements fill all valid prescriptions without unnecessary delay or interference (see S. 778), S3555 [13AP]
———improve implementation of the Medicare prescription drug benefit for individuals who are both Medicare and Medicaid beneficiaries (see S. 1822), S11130 [5OC]
———prohibit coverage of sex-enhancing drugs for individuals convicted of a sex offense (see H.R. 2626), H4072 [25MY]
Members of Congress: ensure that prescription drug coverage for Members is not better than coverage for Medicare beneficiaries (see S. 143), S145 [24JA]
Mental health: protect children and their parents from being coerced into administering psychotropic medication in order to attend school (see H.R. 1790), H2471 [21AP]
National security: prepare and strengthen biodefenses against deliberate, accidental, and natural outbreaks of illness (see S. 1873), S11422 [17OC]
National Vaccine Injury Compensation Program: amend (see H.R. 1297), H1507 [15MR]
Patents: provide for compulsory licensing of certain patented inventions relative to health care emergencies (see H.R. 4102), H9042 [20OC] (see H.R. 4131), H9102 [25OC]
Public Health Service Act: increase affordability of inpatient drugs for Medicaid and safety net hospitals (see S. 1840), S11212 [6OC] (see H.R. 3547), H7558 [28JY]
States: provide with resources needed to rid our schools of performance-enhancing drug use (see S. 1974), S12526 [8NO]
Tariff: aspirin (see S. 1450), S8664 [21JY] (see H.R. 2433), H3555 [18MY]
———ezetimibe (see H.R. 2079), H2976 [4MY]
Taxation: add meningococcal vaccines to the list of taxable vaccines for purposes of the Vaccine Injury Compensation Trust Fund (see S. 1008), S5070 [12MY]
———allow a deduction for amounts paid for health insurance and prescription drug costs of individuals (see H.R. 218), H78 [4JA]
———allow designation of income tax refunds for use in NIH biomedical research programs (see H.R. 370), H233 [26JA]
———allow new investment in, or mergers of biomedical research corporations without limiting tax benefits of net operating losses (see S. 1893), S11559 [19OC] (see H.R. 4082), H8985 [19OC]
———deny deductions for direct-to-consumer advertisements of prescription drugs (see H.R. 575), H351 [2FE]
———impose an excise tax on the termination of retiree prescription drug coverage (see H.R. 462), H284 [1FE]
———repeal the medicine and drugs limitation on the deduction for medical care (see S. 1514), S9158 [27JY] (see H.R. 3428), H6649 [26JY]
———treat expenses for certain meal replacement and dietary supplement products that qualify for FDA-approved health claims as medical care expenses (see H.R. 1545), H1893 [12AP]
Terrorism: provide incentives to commercial researchers to develop technologies and drugs to prevent and treat illnesses associated with a biological, chemical, or radiological weapons attack (see S. 975), S4547 [28AP]
Treaties and agreements: avoid inclusion in future free trade agreements provisions that would restrict access of U.S. consumers to imported prescription drugs (see S. 1551), S9285 [28JY] (see H.R. 3583), H7559 [28JY]
Veterans: expand and enhance health care, mental health, transition, and disability benefits (see S. 13), S142 [24JA]
Factsheets
Medical Isotope Production, S7242 [23JN]
Trade Agreement Impediments to Availability of Patented and Generic Drugs in Developing Countries, S1499 [16FE]
Will Lower Drug Prices Jeopardize Drug Research? Donald Light and Joel Lexchin, American Journal of Bioethics, H5523-H5525 [30JN]
Letters
Compulsory licensing of the influenza medication, Tamiflu: Representatives Kucinich, Sanders, and Berry, E2374 [16NO]
Liability protection to manufacturers of pandemic vaccines: Erwin Chemerinsky, S14247 [21DE], E2650 [22DE]
Maintain current export controls on highly-enriched uranium relative to medical isotope production: John O. Pastore and Robert K. Musil, Physicians for Social Responsibility (organization), S7242 [23JN]
———Nils J. Diaz, NRC, S7238 [23JN]
Medicaid Health Plan Rebate Act: Thomas Johnson, Medicaid Health Plans of America (organization), S9508 [29JY]
Negotiation of fair prices for Medicare prescription drugs: David P. Sloane, AARP, S12283 [2NO]
Pediatric vaccine manufacturer liability protection: Representative Burton, H6983 [28JY]
Prosecution of physicians for prescribing certain controlled substances for pain relief or management: National Association of Attorneys General, E691 [19AP]
Remarks in House
Advertising: prohibit as indecent the broadcasting of any advertisement for a medication for the treatment of erectile dysfunction (H.R. 1420), E498 [17MR]
Africa: develop plan to protect blood supply from infectious diseases, H5286 [28JN]
Astellas Pharma U.S., Inc.: tribute to opening of headquarters, E1393 [28JN]
Asthma Awareness Day: observance, H2746 [3MY]
Braga, Damian: Pocono Mountains Chamber of Commerce Chairman's Business Award recipient, E2246 [3NO]
Brazil: compulsory licensing of AIDS drug in order to produce generic version, E1389 [28JN], E1435 [1JY]
Congress: relationship with special interest groups, H6438 [26JY]
Consumers: development of electronic prescribing systems to improve patient safety and quality of care for patients, H722 [17FE]
———provide tax credit to retirement age individuals, remove barriers to importation, and prohibit certain regulation of Internet sites relative to prescription drugs (H.R. 578), E144 [2FE]
Council of Economic Advisers: prohibit funding to produce a President's economic report regarding a certain average cost of developing and introducing a new prescription drug to the market, H5522-H5526 [30JN]
Courts: pediatric vaccine manufacturer liability protection, H6867, H6868 [27JY], H6983, H7000 [28JY]
———permit civil actions alleging that products claiming to assist in weight loss caused heart disease or other complications, H8935, H8936 [19OC]
———prohibit punitive damages against manufacturers of medical products that comply with FDA standards, H6862-H6867 [27JY], H6986, H6987, H6996, H6999, H7000 [28JY]
———treatment of class action lawsuits involving the arthritis drug Vioxx, H753 [17FE], H6110 [20JY]
Democratic Party: national agenda, H9416-H9418 [28OC]
Dept. of HHS: AIDS Drug Assistance Program funding, E1351 [24JN]
———bar-code medication technology funding, H5072, H5073 [23JN]
———ensure prescription drug clinical trials required to be listed in a public database are listed before a drug is approved for market, H4263, H4264 [8JN]
———give grant preference to States that require schools to allow students to self-administer medication for asthma or anaphylaxis, H2746 [3MY]
———prohibit use of funding to implement a universal mental health screening program, H5145, H5146 [24JN]
———Strategic National Stockpile funding for influenza vaccine production and antiviral treatments, H5033 [23JN]
Dept. of Justice: DEA and Community Oriented Policing Services (COPS) Program funding through reductions in Bureau of the Census funding, H4458, H4459 [14JN]
———prohibit funding to prevent implementation of State laws relative to the use of marijuana for medicinal purposes, H4519-H4524 [15JN], E1312 [22JN]
Dept. of State: Global HIV/AIDS Initiative funding, H5306, H5307 [28JN]
Dept. of Veterans Affairs: pain management research programs funding, H4099 [26MY]
Diseases: authorize assistance to combat HIV/AIDS pandemic in sub-Saharan Africa, H5286, H5295, H5296 [28JN], H6130 [20JY]
———ensure an adequate supply of influenza vaccine and syringes, E2358 [15NO]
———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis, H9311, H9312 [27OC], E2238 [1NO]
———improve preparation for an influenza pandemic, including an avian influenza pandemic, H5714 [12JY], H9073 [25OC], H9280, H9332 [27OC], H9437, H9440, H9441, H9448, H9451 [1NO], H9699, H9939-H9941 [7NO], H10148 [10NO], H11185 [7DE], H12264 [18DE], E2303 [8NO]
———improve preparation for an influenza pandemic, including an avian influenza pandemic (H.R. 3369), H8800 [7OC]
———improve preparation for an influenza pandemic, including an avian influenza pandemic (H.R. 4245), H9932, H9939 [7NO]
Dominican Republic-Central America Free Trade Agreement (DR-CAFTA): impact on the ability of developing nations to acquire generic medications, H6926 [27JY]
Drugs: discrepancy in prescription drug prices between U.S. and foreign countries, H606 [15FE], H1328 [10MR], H1754 [5AP], H3406 [17MY], H4159 [7JN], H4373 [13JN], H4784 [20JN], H4861 [21JN], H5219 [27JN], E1159, E1162 [8JN]
———eliminate safe-harbor exception for certain packaged pseudoephedrine products used in manufacturing methamphetamine (H.R. 1446), H2784 [3MY], H3681 [19MY]
———establish certain restrictions on drugs containing isotretinoin, including the drug marketed as Accutane, H2950 [4MY], H4477 [14JN]
———establish electronic systems in each State for practitioner monitoring of the dispensing of certain controlled substances (H.R. 1132), H6681-H6686 [27JY], E691 [19AP], E1811 [8SE], E1989 [29SE]
———prohibit Federal payment or reimbursement for drugs prescribed for the treatment of sexual or erectile dysfunction, H5126-H5128 [24JN]
———prohibit Federal payment or reimbursement for drugs prescribed to sex offenders for the treatment of sexual or erectile dysfunction, H4988, H5037 [23JN]
———prohibit prosecution of physicians for prescribing certain controlled substances for pain relief or management, E691 [19AP]
———promote fairer prescription drug pricing through Internet sites supported by public-private partnerships, H11658 [15DE]
———provide for importation of pharmaceutical products under a compulsory license as provided for under the World Trade Organization (H.R. 4392), E2424 [18NO]
———provide incentives for investment in research and development of new medicines and to enhance access to new medicines (H.R. 417), E149 [2FE]
———provide incentives to companies to invest in research and development of antibiotic drugs, antivirals, diagnostic tests, and vaccines that may be used to identify, treat, or prevent an infectious disease, H9280 [27OC]
———review expiration dates for prescription drugs, H4300 [9JN]
———transfer ephedrine, pseudoephedrine, and phenylpropanolamine to schedule V of the schedules of controlled substances (H.R. 3955), H10135 [9NO]
FDA: drug and medical device approval process, H815 [1MR]
———ensure autonomy and eliminate conflicts-of-interest relative to drug company fees and advisory panels, H4245-H4247 [8JN]
———establish uniform standards for restocking of unused drugs, H2652 [28AP]
———improve postmarket drug safety, H4206, H4219, H4221, H4242, H4244 [8JN]
———promote competition and drug safety through increased research, E903 [5MY]
———withdraw approved application for the drug known as RU-486 and review process by which the FDA approved such drug, H6209 [21JY]
———withdraw approved application for the drug known as RU-486 and review process by which the FDA approved such drug (H.R. 1079), H1332 [10MR], E357 [3MR]
Federal Food, Drug, and Cosmetic Act: enhance criminal penalties for certain violations involving concealment of evidence of a serious adverse drug experience (H.R. 870), E252 [16FE]
———establish recall authority for drugs and increase criminal penalties for sale or trade of knowingly adulterated or misbranded prescription drugs (H.R. 2345), E950 [12MY]
Foreign countries: remove all embargoes on food, medicine, and medical supplies (H.R. 1527), E575 [7AP]
Global Fund To Fight AIDS, Tuberculosis, and Malaria (organization): funding, H5303 [28JN]
Government regulations: importation of prescription drugs, H418 [9FE], H4220 [8JN], H6654 [27JY]
———importation of prescription drugs (H.R. 328), H1945, H1947 [13AP], H3289 [16MY], H4373 [13JN], H4861 [21JN], H9934 [7NO]
Health: conduct vaccine awareness campaign, ensure sufficient vaccine supply, prepare for pandemic or epidemic, and encourage vaccine production capacity relative to influenza (H.R. 813), H1900 [13AP]
———ensure sufficient vaccine supply, H3586 [19MY]
———improve patient safety and reduce incidence of medical errors, H6999 [28JY]
———improve patient safety and reduce incidence of medical errors (H.R. 3205), H6208 [21JY]
———improve patient safety and reduce incidence of medical errors (S. 544), H6673-H6679 [27JY], H6997 [28JY]
———integrate medical and mental health services to coordinate more effective diagnosis and treatment, H2399 [21AP], H9943-H9945 [7NO]
———link between child vaccinations containing mercury and autism, H481 [9FE], H5074 [23JN], H9451 [1NO]
———provide assistance to combat HIV/AIDS, H10518 [17NO]
———provide liability protection to manufacturers of pandemic vaccines, H12054 [17DE], H12227-H12230 [18DE], H13181 [22DE], E2650 [22DE]
Health care professionals: clarify responsibilities of a pharmacy when a staff pharmacist refuses to fill a valid prescription for a drug on the basis of religious beliefs or moral convictions (H.R. 1652), E658 [15AP]
———reform the medical malpractice system (H.R. 2657), H6408 [25JY]
Lobbyists: impact, H2534 [26AP]
Medicaid: funding, H10150 [10NO]
———GAO study on pharmacy reimbursements for enrollees' prescriptions, H10631 [17NO]
———reform, H10008 [8NO], H10118, H10119, H10123 [9NO], E2409 [18NO], E2443 [6DE]
———require drug utilization review programs to deny coverage of erectile dysfunction drugs for individuals registered (or required to be registered) as sex offenders (H.R. 2648), H5037 [23JN]
———require States to pay dispensing fees to pharmacies for prescriptions, H10639 [17NO]
Medicare: cost estimates for prescription drug benefit program, H526 [10FE], H699 [16FE], H757 [17FE], H3247 [12MY]
———cost of prescription drug benefit coverage implementation, H11275 [8DE], H11510 [14DE]
———coverage of outpatient prescription drugs, H418 [9FE], H1344 [10MR], H6210 [21JY], H8394 [28SE], H8832 [17OC], H8902-H8907 [18OC], H9090 [25OC]
———deliver a meaningful benefit and lower prescription drug prices (H.R. 752), E1940 [22SE]
———ensure that prescription drug benefits have no impact on benefits under other Federal programs (H.R. 2746), E1152 [7JN]
———extend implementation of prescription drug program, H11331 [12DE]
———extend initial enrollment period for prescription drug benefits, waive penalties for late enrollment, and provide other additional beneficiary protections (H.R. 4410), H11189 [7DE]
———improve coordination of prescription drug coverage under retiree plans and State pharmaceutical assistance programs with Medicare drug benefits (H.R. 152), E22 [4JA]
———improve coordination of prescription drug coverage under State pharmaceutical assistance programs with Medicare drug benefits (H.R. 1572), E629 [12AP]
———improve implementation of the Medicare prescription drug benefit, H8651 [6OC]
———permit the Dept. of HHS to enter into direct negotiations to promote the best prices for beneficiaries, H11275 [8DE], H11331 [12DE], H12055 [17DE], E2445 [6DE]
———permit the Dept. of HHS to enter into direct negotiations to promote the best prices for beneficiaries (H.R. 376), H3758 [23MY], H9934 [7NO]
———prescription drug benefit coverage, H9968 [8NO], H10149 [10NO], H10164, H10166, H10167, H10190, H10193, H10195, H10208-H10214 [15NO], H10231, H10232, H10233 [16NO], H11115, H11116, H11184 [7DE], H11508, H11509, H11510 [14DE], H11659 [15DE], E2394 [17NO]
———prescription drug discount card program implementation, H3046 [5MY]
———provide additional beneficiary protections (H.R. 2487), E1046 [20MY]
———provide extended and additional protection to beneficiaries enrolled in prescription drug benefit plans (H.R. 3861), H11511, H11512 [14DE], H12055 [17DE], E1932, E1940 [22SE]
Medicare Prescription Drug, Improvement, and Modernization Act: implementation and funding, H1757-H1763 [5AP]
Medicare/Medicaid: funding, H10007, H10008 [8NO]
Mental health: protect children and their parents from being coerced into administering psychotropic medication in order to attend school (H.R. 1790), H10185-H10187 [15NO], E2379, E2380 [17NO]
Pfizer, Inc.: tribute to humanitarian support for victims of the Indian Ocean tsunami, E298 [18FE]
Republican Party: national agenda, H8729 [6OC]
Richey, John W.: Good Neighbor Pharmacist of the Year award recipient, E2577 [17DE]
Safety: health risks associated with non-FDA-approved inhaled compounded drugs in nebulizers, H2788 [3MY]
Senior citizens: require pharmacists manage and monitor medications for patients with chronic illness, H8737 [7OC]
Taxation: allow a deduction for amounts paid for health insurance and prescription drug costs of individuals (H.R. 218), E18 [4JA]
Treaties and agreements: impact of trade agreements on the pharmaceutical industry, H4312 [9JN]
Veterans: health care funding, H512-H518 [9FE], H604, H621-H626 [15FE], H1572 [16MR]
Remarks in Senate
Advertising: place restrictions on, and study the impact of, direct-to-consumer advertising of prescription drugs, S7876-S7879, S7886 [1JY]
Anabolic Steroid Control Act: technical corrections (S. 893), S4162 [25AP]
Committee on Health, Education, Labor, and Pensions (Senate): legislative agenda, S542 [26JA]
Contraceptives: require equitable coverage of drugs, devices, and services under health insurance plans (S. 1214), S6316-S6318 [9JN]
Democratic Party: national agenda, S110 [24JA]
Dept. of HHS: promulgate regulations for the reimportation of prescription drugs (S. 109), S278 [24JA], S1156 [9FE]
Dept. of Veterans Affairs: permit Medicare-eligible veterans to receive an outpatient medication benefit (S. 614), S2648 [14MR]
Diseases: avian flu prevention and response funding, S4087, S4088 [21AP]
———improve access to HIV/AIDS-related treatments and services in developing countries, S381 [25JA]
———improve and secure an adequate supply of influenza vaccine (S. 1828), S11220-S11222 [6OC]
———improve preparation for an influenza pandemic, including an avian influenza pandemic, S10529-S10531 [28SE], S10652-S10656, S10685-S10693, S10701, S10714 [29SE], S11818 [25OC], S11886-S11889 [26OC], S11958-S11969, S11972, S11978-S11980 [27OC], S12079, S12090, S12096 [1NO], S12805 [15NO], S13605 [15DE], S13948, S13960 [17DE], S14235, S14286, S14288, S14293 [21DE]
———improve preparation for an influenza pandemic, including an avian influenza pandemic (S. 1821), S11132-S11139 [5OC], S11451, S11468 [18OC]
———improve preparation for an influenza pandemic, including an avian influenza pandemic (S. 969), S4581 [28AP], S8447 [19JY], S10626-S10629 [28SE]
———promote initiatives to develop an HIV vaccine (S. Res. 42), S1063 [7FE]
———provide assistance to countries to combat malaria, S8475 [19JY]
———provide assistance to countries to combat tuberculosis, malaria, and other infectious diseases (S. 950), S4568 [28AP]
Drugs: accelerate efforts to develop vaccines for diseases primarily affecting developing countries (S. 1698), S10039, S10043 [14SE]
———discrepancy in prescription drug prices between U.S. and foreign countries, S8397-S8399 [18JY]
———establish an electronic controlled substances monitoring program in each State (S. 518), S2026 [3MR], S6014 [26MY]
———establish electronic systems in each State for practitioner monitoring of the dispensing of certain controlled substances (H.R. 1132), S9584 [29JY]
———expand the clinical trials drug data bank (S. 470), S1797-S1804 [28FE], S13095 [17NO]
———include dehydroepiandrosterone as an anabolic steroid (S. 1137), S6030 [26MY]
———prevent illegal importation of controlled substances (S. 400), S1531 [16FE]
———prohibit Federal payment or reimbursement for drugs prescribed for the treatment of sexual or erectile dysfunction (S. 1113), S5854 [24MY]
———protect the public from unsafe importation of prescription drugs and from counterfeit prescription drugs, S5433 [18MY]
———provide discounts to Medicaid and other Federal programs for the advertising costs of certain prescription drugs and ensure that these drugs are prescribed based on health needs rather than marketing (S. 1128), S6056, S6057 [26MY]
———trade agreement impediments to availability of patented and generic drugs in developing countries, S1498 [16FE]
FDA: condemn delay of decision on the approval of over-the-counter emergency contraceptives, S10249 [21SE]
———ensure autonomy and eliminate conflicts-of-interest relative to drug company fees and advisory panels, S10217 [20SE]
———improve ability to ensure drug safety (S. 930), S4426, S4427 [27AP], S13095 [17NO]
———Inspector General investigation funding relative to delay of decision on the approval of over-the-counter emergency contraceptives, S11907 [26OC]
———withdraw approved application for the drug known as RU-486 and review process by which the FDA approved such drug (S. 511), S2020 [3MR]
Federal Food, Drug, and Cosmetic Act: establish requirements to allow sale of prescription drugs over the Internet (S. 399), S1531, S1534 [16FE]
———preserve effectiveness of medically important antibiotics used in treatment of human and animal diseases (S. 742), S3407 [11AP]
Global Fund To Fight AIDS, Tuberculosis, and Malaria (organization): funding, S2938, S2947 [17MR]
———funding through reductions in Iraq Economic Support Fund funding, S8470, S8471 [19JY]
Government regulations: importation of prescription drugs (S. 334), S1206 [9FE], S1253, S1256 [10FE], S10077 [15SE]
Health: conduct vaccine awareness campaign, ensure sufficient vaccine supply, prepare for pandemic or epidemic, and encourage vaccine production capacity relative to influenza (S. 375), S1415 [15FE]
———ensure vaccine awareness, sufficient vaccine supply, and vaccine production capacity, S3442 [12AP], S3610 [14AP]
———improve accessibility to and administration of immunizations against vaccine-preventable diseases, including influenza (S. 1527), S9292 [28JY]
———improve patient safety and reduce incidence of medical errors (S. 544), S8713, S8714 [21JY], S8741-S8744 [22JY], S9060 [27JY]
———national policy to provide health care and reform insurance procedures, S15-S18 [4JA]
———promote a culture of safety within the health care system through the establishment of a National Medical Error Disclosure and Compensation Program (S. 1784), S10599 [28SE]
———provide compensation for injuries resulting from smallpox countermeasures, provide protection against chemical or radiological agents, increase distribution of vaccines, and improve vaccine injury compensation, S1598 [17FE]
———provide liability protection to manufacturers of pandemic vaccines, S14142-S14146 [20DE], S14234-S14238, S14242-S14244, S14246, S14249 [21DE], S14424 [22DE]
———require notification by manufacturers before discontinuing production of a vaccine and develop a national vaccine stockpile (S. 226), S741 [1FE]
———safety of vaccines containing mercury and thimerosal, S11994 [27OC]
Health care facilities: provide for public disclosure of charges for certain hospital services and drugs (S. 1827), S11220 [6OC]
Health care professionals: clarify responsibilities of a pharmacy when a staff pharmacist refuses to fill a valid prescription for a drug on the basis of religious beliefs or moral convictions (S. 809), S3685 [14AP]
India: provide assistance to combat HIV/AIDS (S. 674), S3055 [17MR]
Japan: urge honoring of commitments under the Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals (S. Con. Res. 67), S13402 [18NO]
Medicaid: clarify treatment of prescription drug distributor service fees, S14205 [21DE]
———contain costs of prescription drug program, S2145 [7MR]
———eliminate increase in rebate for generic drugs, S12318, S12319 [3NO]
———ensure that rural remote pharmacies receive reimbursements for enrollees' prescriptions, S12325 [3NO]
———exclude discounts provided to mail order and nursing facility pharmacies from the determination of average manufacturer price, S12318 [3NO]
———exclude prompt-pay discounts from pharmacy reimbursement methodology, S12327 [3NO]
———extend prescription drug rebate program to enrollees of managed care organizations (S. 1585), S9507 [29JY]
———require States to pay dispensing fees to pharmacies for prescriptions, S12326 [3NO]
Medicare: continue Medicaid prescription drug coverage to dual-eligible beneficiaries for a certain period while allowing part D benefits to be implemented as scheduled, S11853-S11855, S11858 [26OC]
———continue Medicaid prescription drug coverage to dual-eligible beneficiaries for a certain period while allowing part D benefits to be implemented as scheduled (S. 566), S2270 [8MR], S13342 [18NO]
———coverage of outpatient prescription drugs, S2604 [14MR]
———deliver a meaningful benefit and lower prescription drug prices (S. 345), S1272, S1273 [10FE]
———deliver a meaningful benefit and lower prescription drug prices (S. 873), S4137 [21AP], S4157 [22AP], S10525 [27SE]
———improve coordination of prescription drug coverage under State pharmaceutical assistance programs with Medicare drug benefits (S. 764), S3487 [12AP]
———negotiate for lower prices for prescription drugs (S. 813), S3747 [15AP]
———permit negotiation of fair prices for, and allow the reimportation of, prescription drugs, S2821-S2825 [16MR], S2921, S2953 [17MR]
———permit negotiation of fair prices for, and allow the reimportation of, prescription drugs (S. 239), S745-S747 [1FE], S877 [2FE], S1152 [9FE], S1252, S1253 [10FE], S1321 [14FE], S1597 [17FE]
———prescription drug discount card program implementation, S132-S134 [24JA]
———provide extended and additional protection to beneficiaries enrolled in prescription drug benefit plans, S13119, S13128, S13129 [17NO]
———provide extended and additional protection to beneficiaries enrolled in prescription drug benefit plans (S. 1841), S11231 [6OC], S12726 [14NO], S12826-S12828 [15NO]
———provide extended and additional protection to beneficiaries enrolled in prescription drug benefit plans (S. 1841), unanimous-consent request, S12828 [15NO]
———provide for negotiation of fair prices for prescription drugs, S12282-S12284 [2NO], S12324, S12325, S12346 [3NO]
———provide for negotiation of fair prices for prescription drugs (S. 123), S315 [24JA]
———provide for negotiation of fair prices for prescription drugs (S. 445), S1658 [17FE], S13342 [18NO]
———reform and provide prescription drug coverage, S16 [4JA]
———repeal Medicare Advantage Regional Plan Stabilization Fund (S. 124), S316 [24JA]
———require certification prior to beneficiary enrollment in a prescription drug plan, S12313 [3NO]
———require that prescription drug plans or Medicare Advantage-Prescription Drug plans with initial coverage limits obtain signed certification prior to enrolling benficiaries (S. 2026), S12958 [16NO]
Medicare/Medicaid: assist pharmacies in facilitating enrollment of dual eligible populations under the prescription drug benefit (S. 2173), S14334 [21DE]
———ensure that pharmacies receiving reimbursements fill all valid prescriptions without unnecessary delay or interference (S. 778), S3564 [13AP]
———improve implementation of the Medicare prescription drug benefit for individuals who are both Medicare and Medicaid beneficiaries, S12202-S12207 [2NO], S12309 [3NO]
———improve implementation of the Medicare prescription drug benefit for individuals who are both Medicare and Medicaid beneficiaries (S. 1822), S11139 [5OC], S11853-S11855 [26OC]
NRC: maintain current export controls on highly-enriched uranium relative to medical isotope production, S7236-S7244, S7247, S7248, S7250 [23JN]
Office of the U.S. Trade Representatives: prevent negotiation of trade agreements that prevent the U.S. from changing patent laws to allow the importation of pharmaceutical product, S10077, S10078 [15SE]
Public Health Service Act: increase affordability of inpatient drugs for Medicaid and safety net hospitals (S. 1840), S11230 [6OC]
Republican Party: national agenda, S4226 [26AP]
Senate: accomplishments of the 108th Congress, S13-S15 [4JA]
Social Security: advertising campaign designed to build public support for privatization proposals, S547 [26JA]
States: provide with resources needed to rid our schools of performance-enhancing drug use (S. 1974), S12530 [8NO]
Taxation: allow new investment in, or mergers of biomedical research corporations without limiting tax benefits of net operating losses (S. 1893), S11567 [19OC]
———repeal the medicine and drugs limitation on the deduction for medical care (S. 1514), S9185 [27JY]
Terrorism: provide incentives to commercial researchers to develop technologies and drugs to prevent and treat illnesses associated with a biological, chemical, or radiological weapons attack, S14237 [21DE]
———provide incentives to commercial researchers to develop technologies and drugs to prevent and treat illnesses associated with a biological, chemical, or radiological weapons attack (S. 975), S4590-S4595, S4607 [28AP], S4787 [9MY], S9433 [29JY], S11602 [20OC]
University of Kentucky: College of Pharmacy recipient of American Pharmacists Association Pinnacle Award, S6469 [14JN]
Veterans: expand and enhance health care, mental health, transition, and disability benefits (S. 13), S111, S168 [24JA], S510-S512 [26JA]
———health care funding, S2720-S2726 [15MR], S2788-S2793, S2806, S2807 [16MR]
Reports filed
Biodefense and Pandemic Vaccine and Drug Development Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1873), S11768 [24OC]
National All Schedules Prescription Electronic Reporting Act: Committee on Energy and Commerce (House) (H.R. 1132) (H. Rept. 109-191), H6932 [27JY]
———Committee on Health, Education, Labor, and Pensions (Senate) (S. 518) (S. Rept. 109-117), S9466 [29JY]
Patient Safety and Quality Improvement Act: Committee on Energy and Commerce (House) (H.R. 3205) (H. Rept. 109-197), H6932 [27JY]
Statements
Maintain Current Export Controls on Highly-Enriched Uranium Relative to Medical Isotope Production: Physicians for Social Responsibility (organization), S7242 [23JN]
Medicaid Drug Rebate Program Extension to Enrollees of Managed Care Organizations: American Public Human Services Association, S9508 [29JY]
Summaries
Medicaid Health Plan Rebate Act (S. 1585), S9507 [29JY]
Patient Safety and Quality Improvement Act (S. 544), S8741 [22JY]
Trade Agreements and Access to Medications Under the Bush Administration: Committee on Government Reform (House), H6926 [27JY]
Tables
Proposed VA budget for fiscal year 2006, S2723 [15MR]
Texts of
H.R. 1132, National All Schedules Prescription Electronic Reporting Act, H6681-H6683 [27JY]
H.R. 1790, Child Medication Safety Act, H10185 [15NO]
S. 13, Fulfilling Our Duty to America's Veterans Act, S169-S174 [24JA]
S. 109, Pharmaceutical Market Access Act, S278-S282 [24JA]
S. 123, Efficiency in Government Health Care Spending Act, S315 [24JA]
S. 124, repeal Medicare Advantage Regional Plan Stabilization Fund, S316 [24JA]
S. 143, Taste of Our Own Medicine Act, S363 [24JA]
S. 173, Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act, S580 [26JA]
S. 226, Improved Vaccine Supply Act, S741 [1FE]
S. 345, Medicare Prescription Drug Savings and Choice Act, S1273 [10FE]
S. 399, Internet Pharmacy Consumer Protection Act, S1532-S1534 [16FE]
S. 400, Prevention of Illegally Imported Controlled Substances Act, S1534 [16FE]
S. 445, Medicare Prescription Drug Price Reduction Act, S1659 [17FE]
S. 470, Fair Access to Clinical Trials (FACT) Act, S1798-S1803 [28FE]
S. 511, RU-486 Suspension and Review Act, S2020 [3MR]
S. 544, Patient Safety and Quality Improvement Act, H6673-H6676 [27JY]
S. 566, Medicare Dual Eligible Prescription Drug Coverage Act, S2271 [8MR]
S. 674, provide assistance to combat HIV/AIDS in India, S3056 [17MR]
S. 764, Preserving Access to Affordable Drugs Act, S3487 [12AP]
S. 809, Access to Legal Pharmaceuticals Act, S3685 [14AP]
S. 813, negotiate for lower prices for Medicare prescription drugs, S3747 [15AP]
S. 873, Medicare Prescription Drug Savings and Choice Act, S4114 [21AP]
S. 893, Anabolic Steroid Control Act technical corrections, S4162 [25AP]
S. 969, Attacking Viral Influenza Across Nations Act, S4582-S4585 [28AP]
S. 1126, prohibit Federal payment or reimbursement for drugs prescribed to sex offenders for the treatment of sexual or erectile dysfunction, S5933 [25MY]
S. 1137, include dehydroepiandrosterone as an anabolic steroid, S6031 [26MY]
S. 1514, OTC Medicine Tax Fairness Act, S9185 [27JY]
S. 1585, Medicaid Health Plan Rebate Act, S9508 [29JY]
S. 1698, Vaccines for the New Millennium Act, S10040-S10043 [14SE]
S. 1821, Pandemic Preparedness and Response Act, S11133-S11138 [5OC]
S. 1827, Hospital Price Reporting and Disclosure Act, S11220 [6OC]
S. 1841, Medicare Informed Choice Act, S11231 [6OC]
S. 1873, Biodefense and Pandemic Vaccine and Drug Development Act, S11424-S11433 [17OC]
S. 1893, Biotechnology Future Investment Expansion Act, S11567 [19OC]
S. 1974, Drug Free Varsity Sports Act, S12530 [8NO]
S. 2026, Medicare Prescription Drug Gap Disclosure Act, S12959 [16NO]
S. Con. Res. 67, urge Japan to honor commitments under the Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals, S13401, S13403 [18NO]
S. Res. 42, promote initiatives to develop an HIV vaccine, S1063 [7FE]
Transcripts